Dan Ivan, countryhead of Sanofi-Aventis, the largest player on the Romanianpharmaceutical market, says the group could relocate production ofseveral drugs to its Bucharest plant, which became part of thegroup's portfolio when it acquired Czech company Zentiva.
The first stage islikely to include four products, but the number is not final. Theyare antibiotics and antihypertensive drugs, but the company hadalso previously announced plans to manufacture a urology drug aimedexclusively at the German market.
"Those in charge ofindustrial operations in Prague (Zentiva's headquarters) plan touse more of the capacity of the Romanian production facility. Thereare further drugs whose production will be transferred to theformer Sicomed plant within the group. We will start with a seriesof four, but this is not relevant because we are dependent on thevolumes of sales of these products," said Dan Ivan, 51, who is alsochairman of Zentiva's Board of Directors.
The overallproduction capacity of the Romanian plant is 100 million units, butonly around 64-70% of it is used.
According to marketanalysis and research company Cegedim, Sanofi-Aventis (Zentivaincluded) posted 815.7 million RON (194 million euros) in sales onthe Romanian market and had a 10.1% market share.
"I think we couldeven be congratulated if we preserve 2009's level, with differencesfrom one product to another," Ivan added.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
